Technology

Leap Therapeutics

$2.48
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.06 (+2.48%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell LPTX and other stocks, options, and ETFs commission-free!

About LPTX

Leap Therapeutics, Inc. Common Stock, also called Leap Therapeutics, is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01, which is a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1 and TRX518, which is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA. The listed name for LPTX is Leap Therapeutics, Inc. Common Stock.

CEO
Doug E. Onsi
Employees
26
Headquarters
Cambridge, Massachusetts
Founded
2011
Market Cap
146.73M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
734.09K
High Today
$2.67
Low Today
$2.36
Open Price
$2.39
Volume
1.03M
52 Week High
$3.18
52 Week Low
$1.15

Collections

LPTX Earnings

-$0.55
-$0.37
-$0.18
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 15, Pre-Market

You May Also Like

EWY
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure